ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2374

Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects

Jeffrey Voss1, Candace Graff2, Annette Schwartz3, Deborah Hyland4, Maria Argiriadi4, Heidi Camp5, Lori Dowding4, Michael Friedman4, Kristine Frank5, Jonathon George4, Eric Goedken4, Gloria Lo Schiavo4, Michael Morytko4, Robert o'Brien4, Robert Padley6, Matthew Rosebraugh5, Michael Rozema5, Kent Stewart5, Grier Wallace4, Neil Wishart4, Anwar Murtaza7 and Lisa Olson3, 1Immunology, AbbVie Pharmaceuticals, Worcester, MA, 2Drug Metabolism and Pharmacokinetics, Abbvie Pharmaceuticals, worcester, MA, 3AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4Abbvie Pharmaceuticals, worcester, MA, 5abbvie pharmaceuticals, north chicago, IL, 6AbbVie, Inc, North Chicago, IL, 7Broad Institute, Cambridge, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Anemia, Biomarkers, Janus kinase (JAK), Natural killer (NK) cells and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there are still many RA patients who fail to experience substantial decreases in disease activity. Recently, Jak kinase blockade was shown clinically to be effective in managing disease and in some cases achieving remission. However, these first generation Jak inhibitors have failed to meet expectations due to dose-limiting tolerability and safety issues. ABT-494 is a second generation Jak kinase inhibitor with high selectivity for Jak1 thereby minimizing the potential for side effects related to Jak2 and Jak3 inhibition. Here we describe preclinical and early clinical data that suggest ABT-494 has potential to address some of the current unmet medical needs of RA patients.

Methods:

ABT-494 was engineered for increased selectivity for Jak1 using structural predictions that indicated the potential for differential binding interactions outside the ATP-binding active site of Jak1 but not Jak2. The efficacy and selectivity of ABT-494 were tested in a battery of relevant cellular and in vivopharmacology assays including bone marrow colony formation, adjuvant induced arthritis (AIA), erythropoietin induced reticulocyte deployment and NK/NKT cell suppression. The potency of ABT-494 in a variety of complementary pharmacodynamic assays was also assessed at multiple dosages in healthy human subjects administered orally for 14 days.

Results:

ABT-494 demonstrates approximately 74 fold selectivity for Jak1 over Jak2 in cellular assays dependent on specific, relevant cytokines. ABT-494 is a potent inhibitor of inflammation and bone loss in rat AIA and, compared to Tofacitinib, spares relevant essential physiological processes such as erythropoietin signaling and peripheral NK cell counts at similarly efficacious doses in rats. When dosed orally for 14 days in healthy human subjects ABT-494 did not decrease reticulocyte or NK cell counts at predicted efficacious doses consistent with its pharmacodynamic properties in rats.

Conclusion:

ABT-494 is a Jak1-selective inhibitor that demonstrates efficacy in rat arthritis models. Preliminary evidence suggests that pharmacodynamic properties of ABT-494 are consistent between those observed in rodent models and in healthy human subjects. Taken together, these encouraging observations support further testing of ABT-494 in RA patients in Phase II randomized placebo controlled trials and indicate it may have increased potential to address patient needs over existing agents.

The design, study, conduct and financial support for the clinical trial and research was provided by AbbVie. AbbVie participated in the interpretation of data, review and approval of this disclosure. AM was an employee of AbbVie at the time of data collection and analysis.  .


Disclosure:

J. Voss,

Abbott Immunology Pharmaceuticals,

3;

C. Graff,

Abbott Immunology Pharmaceuticals,

3;

A. Schwartz,

Abbott Immunology Pharmaceuticals,

3;

D. Hyland,

Abbott Immunology Pharmaceuticals,

3;

M. Argiriadi,

Abbott Immunology Pharmaceuticals,

3;

H. Camp,

Abbott Immunology Pharmaceuticals,

3;

L. Dowding,

Abbott Immunology Pharmaceuticals,

3;

M. Friedman,

Abbott Immunology Pharmaceuticals,

3;

K. Frank,

Abbott Immunology Pharmaceuticals,

3;

J. George,

Abbott Immunology Pharmaceuticals,

3;

E. Goedken,

Abbott Immunology Pharmaceuticals,

3;

G. Lo Schiavo,

Abbott Immunology Pharmaceuticals,

3;

M. Morytko,

Abbott Immunology Pharmaceuticals,

3;

R. o’Brien,

Abbott Immunology Pharmaceuticals,

3;

R. Padley,

Abbott Immunology Pharmaceuticals,

3;

M. Rosebraugh,

Abbott Immunology Pharmaceuticals,

3;

M. Rozema,

Abbott Immunology Pharmaceuticals,

3;

K. Stewart,

Abbott Immunology Pharmaceuticals,

3;

G. Wallace,

Abbott Immunology Pharmaceuticals,

3;

N. Wishart,

Abbott Immunology Pharmaceuticals,

3;

A. Murtaza,

Abbott Immunology Pharmaceuticals,

1;

L. Olson,

Abbott Immunology Pharmaceuticals,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacodynamics-of-a-novel-jak1-selective-inhibitor-in-rat-arthritis-and-anemia-models-and-in-healthy-human-subjects/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology